We're growing our R&D team and #hiring a new Senior Molecular Biologist in Stevenage. This is an exciting opportunity to join a small team and play a meaningful role in expanding our in-house molecular biology work.
About us
An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2021
Employees at Serna Bio
-
Paul Bradley-Law
People and Operations Strategy
-
Neil Kubica
Entrepreneurial leader driven to unlock the full potential of the genome for drug discovery and development
-
Harini Srinivasan
Head of Platform Biology at Serna Bio
-
Josephine Joel
Principal Scientist | Team Leader | Molecular Biologist | AAV Scientist | Project Manager
Updates
-
ARTEM allows for automated searches of RNA structure databases to identify 3D structure motifs. Baulin et al: https://lnkd.in/ekeWzKVD
-
The transcriptome is the next frontier in drug discovery. Hear comments from Rabia T. K. and Anne Horgan (nee Nguyen) on the subject. Thank you TTP plc for the interview #RNADay https://lnkd.in/dmvF2mxh
Small Molecules: Can new classes of drug target reinvigorate drug discovery?
https://www.ttp.com
-
Our CEO, Rabia T. K., sat down with Drug Discovery World to discuss the applications of ML/AI to drug discovery and the considerable potential that could be unlocked by developing an understanding of RNA architecture. https://lnkd.in/dVDTmnmm
The untapped potential of the transcriptome - Drug Discovery World (DDW)
https://www.ddw-online.com
-
Great new paper from the Yeo lab: Mudskipper detects combinatorial RNA binding protein interactions in multiplexed CLIP data https://lnkd.in/e_sYzSt6
cell.com
-
Since our first day of business in 2021 we have maintained a pledge on our website to support women looking to re-engage with the TechBio world after a career break. We're serious about making these opportunities a reality. If you're looking to get back into the sector after a break, please do reach out to our VP of People Paul Bradley-Law
-
Insights into the molecular mechanisms of UTR mutations and their links to clinical impacts through translation defects in this paper from Wei-Ping Li et al: https://lnkd.in/eHDyUxJE
Massively Parallel Polyribosome Profiling Reveals Translation Defects of Human Disease-Relevant UTR Mutations
biorxiv.org
-
SHAMAN - A computational technique to identify potential small-molecule binding sites in RNA structural ensembles using atomistic molecular dynamics simulations in this paper by Panei et al: https://lnkd.in/efUcC_B6
Identifying small-molecules binding sites in RNA conformational ensembles with SHAMAN
ncbi.nlm.nih.gov
-
We are looking for our first BD hire, to build the company as a member of the leadership team. Know someone - please ask them to get in touch with Paul Bradley-Law https://lnkd.in/e9UrUz6z
Vice President of Business Development - Serna Bio
apply.workable.com
-
Serna Bio is a remote-first company spread across two continents. We have carefully designed ways of working which allow us to rapidly progress work in an interdisciplinary, international environment. But every six months we spend a week together to review our progress and plan for the future. The opportunity to connect, celebrate successes, break bread with one another, and Escape (or fail to escape) Rooms is a force accelerator for our work and a highlight of the calendar.
-